Press Releases

RSS
  • Apr 5, 2016
    ENGLEWOOD, Colo., April 5, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, observed encouraging data from two prospective studies of its MiOXSYS™ System that demonstrated its clinical utility as a tool for measuring oxidation-reduction potential (ORP) to assess the degree of oxidative stress ...
    Mar 31, 2016
    ENGLEWOOD, Colo., March 31, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on global commercialization of novel products in the field of urology, has obtained Health Canada Class II Medical Device approval for its MiOXSYS™ System. MiOXSYS is the company's in vitro diagnostic platform for assessing the level of oxidative stress i...
    Mar 29, 2016
    ENGLEWOOD, Colo., March 29, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced that the company has entered into a co-promotion agreement for Primsol® (trimethoprim hydrochloride) oral solution with Allegis Pharmaceuticals, a commercial-stage specialty pharmaceu...
    Mar 1, 2016
    ENGLEWOOD, Colo., March 1, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced that it has entered into a study agreement with Hybridyne Imaging Technologies to investigate the efficacy of Hybridyne's ProxiScan™ compact gamma cameras to detect local prostate can...
    Feb 16, 2016
    ENGLEWOOD, Colo., Feb. 16, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended December 31, 2015....
    Feb 11, 2016
    ENGLEWOOD, Colo., Feb. 11, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the Company will present its operational results for the second fiscal quarter of 2016 on Tuesday, February 16, 2016, at 4:30 p.m. ET.  The Company will review recent accomplishments and pr...
    Feb 9, 2016
    ENGLEWOOD, Colo., Feb. 9, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced the first commercial sales of its MiOXSYS™ System in Europe and the Middle East.  MiOXSYS is the company's in vitro diagnostic platform for assessing the level of oxidative stress in s...
    Feb 3, 2016
    ENGLEWOOD, Colo., Feb. 3, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, announced today that the Company will present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference, taking place in New York on February 10-11, 2016....
    Jan 27, 2016
    ENGLEWOOD, Co., Jan. 27, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, today announced that Josh Disbrow, Aytu's Chief Executive Officer, and Jarrett Disbrow, Aytu's Chief Operating Officer, have been added to the Aytu Board of Directors. The two will join Michael Macaluso, who r...
    Jan 12, 2016
    ENGLEWOOD, Colo., Jan. 12, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, today announced that it has obtained CE Marking in Europe for its MiOXSYS™ System.  MiOXSYS is the company's in vitro diagnostic platform for assessing the level of oxidative stress in semen as an aid in...